Progyny, Inc. (PGNY)

From the record

Progyny, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Progyny, Inc.'s 6 filed years say what it did: revenue went from $345 million in fiscal 2020 to $1.3 billion in fiscal 2025, up 30.2% a year; it rose in 5 of 5 years; it never fell from a peak; net income was positive in 6 of 6 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Progyny, Inc.'s diluted share count shrank about 3.5% a year, and dividends and buybacks returned about 66% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 37 sales (32 under scheduled 10b5-1 plans) and 1 purchase of their own stock on the open market in the year to 2026-11-12, buying about $2 million (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Progyny, Inc. earned about 11 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 41 cents per dollar of everything the company owns. Leverage: it owed about 30 cents per dollar of assets, and net share issuance: its share count shrank 5.9% over the year (the filed statements).

From the record

Progyny, Inc.'s standing among 10 graded names in its industry family: revenue of $1.3 billion in fiscal 2025 ranks in the top 28% by size; a net margin of 4.5% ranks in the bottom 45%; revenue growth of 17.9% a year over the last 3 filed years ranks in the top 45% (its annual reports).

From the record

Progyny, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Anevski, Peter (CHIEF EXECUTIVE OFFICER, as filed), filing under that title since 2022-01-03, 4.9 years (bottom 44% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 6 years (top 36%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (top 39%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Progyny, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $112 million against no long-term debt tagged leaves 15.1% of its assets as net cash, top 15% of its family; cash from operations less capital spending is 14.9% of revenue (top 15%); a gross margin of 23.6% (bottom 19%); research spending of 0.7% of revenue (bottom 10%) (its annual report).

From the record

Progyny, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 17.9% a year over the last three filed years against 30.2% over all 6, slowing (bottom 5% of its family); the newest year grew 10.4% (top 15%); capital spending grew 78.4% a year (top 5%) (its annual reports). Progyny, Inc. reported 2 product lines in fiscal 2025: Fertility Benefit Services at $831 million (65%), Pharmacy Benefit Services at $458 million (36%); 2 of 2 grew against the year before (its annual report).

From the record

Progyny, Inc.'s newest year against its own record: revenue of $1.3 billion in fiscal 2025 came in 9.3% below the $1.4 billion its prior three years' pace pointed to (bottom 35% of its family); net income of $59 million against a prior three-year average of $49 million (top 45%); a net margin of 4.5% against 4.7% before (bottom 35%) (its annual reports).